KB-1368

Tralokinumab

45576

Background of Tralokinumab

Tralokinumab is a fully human monoclonal antibody designed to treat moderate to severe atopic dermatitis (AD) by specifically neutralizing interleukin-13 (IL-13), a key cytokine driving the peripheral inflammation characteristic of AD. Its efficacy and safety have been evaluated in several clinical trials, making it a significant advancement in the management of AD. Tralokinumab represents a significant advancement in the treatment of moderate to severe atopic dermatitis, offering a new therapeutic option for patients who have not responded adequately to conventional therapies. Its ability to specifically target IL-13 and its demonstrated efficacy in improving both the physical symptoms and quality of life for patients with AD underscore its value in dermatological care.

Specifications

Catalog Number	KB-1368
Antibody Name	Tralokinumab
Isotype	Human IgG4,lambda
FC Muations	Wild Type
Target	IL13
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R: Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019 Jan;143(1):135-141.
Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, Szymczak S, Swindell WR, Sarkar MK, Raja K, Shao S, Patrick M, Gao Y, Uppala R, Perez White BE, Getsios S, Harms PW, Maverakis E, Elder JT, Franke A, Gudjonsson JE, Weidinger S: Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019 Jul;139(7):1480-1489.